Eli Lilly Israel Ltd

Antimetabolite (antifolate). Pemetrexed 500 mg, 100 mg.
VIAL: 1X 100 mg, 500 mg. Comb. use
with cisplatin: 500 mg/m2 I.V. over 10
mins. on day 1 of each 21-day cycle.
Recommend. dose cisplatin: 75 mg/m2
I.V. over 2 hrs. begin. 30 mins. aft. end
of Alimta admin.
Monother: 500 mg/m2 IV over 10 mins.
on the 1 day of each 21-day cycle. See
lit.
In comb. with cisplatin for tmt.: malignant
pleural mesothelioma whose dis.
unresectable or otherwise not candidates
for curative surg.; first line tmt. locally
advanced/ metastat. non-small cell
lungcancer other than predom. Squamous
cell histology. As monother: in local.
advanced/ metastat. non-small cell lung
cancer other than predom. squamous cell
histology histology in patients whose dis.
has not progressed immediately following
platinum-based chemotherapy; second
line tmt. locally advanced/metastat.
nonsmall cell lung cancer, other than
predom. squamous cell histology.
C/I: Hypersens., lact., concom. yellow
fever vaccine.

Long Acting Insulin. Insulin Glargine 100 U/ml.
Cartridge (sol. for inj.): 5×3 ml
Pre-filled Pen (sol.for inj.): 5 ×3 ml
Should be admin. once dly. at any time but at the same time each day.
Dose regimen should be individ. adjust. In pts. with type 2 diabetes mell., the drug can also be given together with orally active antidiabetic med. products.
The potency of this med. product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analog. See lit.
Tmt. of adult pts. 18 yrs. and over with type 1 or type 2 diabetes mell. who require basal (long act.) insulin for the control of hyperglycaem.
C/I: Hypersens.

Phosphodiesterase-5 Enzyme Inhibitor. Tadalafil 2.5, 5, 10, 20 mg.
F.C. TABS: 4 x 10 mg; 4, 8 x 20
mg. On-demand: 10 mg or 20 mg,
depend. response, 30 mins. - 12 hrs
bef. Sexual activity. Effic. may persist
for up to 36 hrs. Max: 1 dose dly, but
dly use not recommend. Child: Under
18 yrs: Not recommend.
F.C. TABS: 28 x 2.5 mg, 5 mg. Onceaday:
For men who anticipate freq. use
(min. 2 x wkly): 2.5 mg/5 mg 1 x dly,
depend. on individ. tolerabil. Reassess period. See lit.
Treatment of erectile dysfunction
(ED) in adult men. Also indicated for the
treatment of the signs and symptoms of
benign prostatic hyperplasia (BPH), also
indicated for the treatment of ED and the
signs and symptoms of BPH (ED/BPH).
CIALIS is not indicated for use by women.
C/I: Co-adminis. nitrates. Card.dis. I,Uns.
ang. uncont. Arrhythmias,
hypotens. Uncontr. Hypertens. Use by
women, see lit.

SNRI. Duloxetine HCl 30 mg, 60 mg.
CAPS: 7,14,28 x 30 mg, 60 mg.
intial: 30 mg dly. maint: 60 mg dly.
Ther. response: 2-4 wks aft. tmt. To
discont: Taper by 1/2 dose (30 mg) dly
or on alt. days. See lit.
Major depress. episodes., Generalized
anxiety dis., Neuropath. pain assoc.
with diabet. periph. neuropathy.,
fibromyalg., chron. muscoskeletal pain.
C/I: Concom. use with MAOI,
uncontrolled narrow-angle glaucoma.

Antiplatelet Agent. Prasugrel HCl 5 mg, 10 mg.
F.C. TABS: 28 X 5mg ,10 mg.
Initial: 60 mg load. dose, cont. with 10
mg 1 x dly (with ASA 75-325 mg dly).
Pts. at incr. risk bleed (>75 yrs or
weight <60 kg): 5 mg maint. dose. Tmt.
up to 12 mths. recommend.
Co-administered with ASA to prevent.
atherothrombot. events in pts.
with acute coron. syndr. (unstable angina,
non-ST seg. elevat. MI [UA/ MSTEMI] or ST
seg. elevat. MI [STEMI]) undergoing prim./
delayed PCI. The incr. effic. to be balanced
with incr. risk in pts. with bleed. tend. in
those with past TIA/ CVA and those >75 yrs
and wt. <60 kg.
C/I: Hypersens., active path. bleed.,
history stroke or TIA, severe hepat.
impair. (Child Pugh class C).

Selective Estrogen Receptor Modulator (SERM). Raloxifene HCl 60 mg.
F.C. TABS: 28. 1 tab. dly without regard to
meals.
Tmt. osteoporos. in post-menopaus.
women. Tmt., prevent. osteoporos. in postmenopaus.
women in whom estrogen
ther. unsuitable. Reduct. risk invasive
breast cancer in postmenopaus. women
with osteoporos. Reduct. risk invasive
breast cancer in women at high risk of
invasive breast cancer.
C/I: Pregn. or possibility thereof, lact.,
active/history of venous thromboembol.
events, deep vein thrombos.,
pulm. embol., retinal vein thromb.